Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The impact of Parkinson's disease (PD) and its pharmacologic treatment on health-related quality of life (HRQL) and economic outcomes is reviewed. PD is a chronic and progressive neurologic ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.

The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...

This ability to detect the disease early could dramatically change the way doctors approach the treatment of Parkinson’s, potentially leading to earlier, more effective interventions.